YZYumin Zhou

Yumin Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yumin Zhou has a total of 401 co-authors. Here are the top co-authors by number of shared publications:

  • Pixin Ran

    State Key Laboratory of Respiratory Diseases National Clinical Research Center for Respiratory Diseases Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong China

    65 shared publications
  • Zhishan Deng

    State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Diseases & National Center for Respiratory Medicine & Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China

    38 shared publications
  • Xiaohui Wu

    State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Diseases & National Center for Respiratory Medicine & Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China

    33 shared publications
  • Fan Wu

    State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease & National Center for Respiratory Medicine & Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China

    31 shared publications
  • Kunning Zhou

    State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Diseases & National Center for Respiratory Medicine & Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China

    31 shared publications
  • Fan Wu

    The First Affiliated Hospital of Guangzhou Medical University State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Diseases & National Center for Respiratory Medicine & Guangzhou Institute of Respiratory Health Guangzhou

    28 shared publications

Latest Publications

  • Open Access

    Tiotropium and clinically important deterioration in mild-to-moderate chronic obstructive pulmonary disease: a post hoc win ratio analysis of the Tie-COPD study

    by Yinghui Jiang, Fan Wu, Junfeng Lin, Qi Wan, Kunning Zhou, Xiaohui Wu, Zhishan Deng, Zihui Wang, Pixin Ran, Yumin Zhou

    Background Clinically important deterioration (CID) has been used to assess chronic obstructive pulmonary disease (COPD) progression by time-to-first-event analysis. However, this does not reveal the clinical importance of the CID components. The win ratio may provide a complementary assessment by comparing outcomes according to a prespecified hierarchy. We reanalysed data from the Tie-COPD studywith win ratio to assess the overall treatment benefit associated with tiotropium in patients with mild-to-moderate COPD.Methods In this exploratory post hoc study, the unmatched win ratio method was applied to the outcomes observed in the Tie-COPD study comparing 18 µg tiotropium with placebo in patients with mild-to-moderate COPD over 24 months. CID was defined as an occurrence of moderate-to-severe exacerbation, an increase of ≥2 units in COPD Assessment Test (CAT) score or a decrease of ≥100 mL in the forced expiratory volume in 1 s (FEV 1). We evaluated the win ratio across all possible hierarchies of CID components. Exploratory inverse-probability-of-censoring weighted (IPCW), and covariate-adjusted IPCW (CovIPCW) analyses were performed to account for censoring. Subgroup analyses were performed with stratification by sex, smoking status, Global Initiative for Chronic Obstructive Lung Disease stage, CAT score and modified Medical Research Council score at baseline.Results Of the 841 randomised patients, 771 were included in the full analysis set (tiotropium=388; placebo=383). With the clinical hierarchy of CID defined by FEV 1, exacerbation and CAT, the win ratio was 2.26 (95% CI 1.87 to 2.73, p<0.001), and the net benefit was 0.35 (95% CI 0.27 to 0.44, p0.05).Conclusions In this exploratory post hoc analysis, tiotropium was associated with a greater overall treatment benefit than placebo in patients with mild-to-moderate COPD. This benefit was also observed in patients with mild disease or fewer respiratory symptoms. The direction of the findings was consistent across alternative CID hierarchies and censoring-adjusted analyses.Trial registration number NCT01455129.

  • Open Access

    Association between Airway Mucus Plugs on Computed Tomography and Respiratory Outcomes in Participants with COPD and with Preserved Spirometry: Findings from a Chinese Population

    by Fan Wu, Fangyan Wu, Tingting Xia, Kunning Zhou, Zhishan Deng, Qi Wan, Gaoying Tang, Suyin Huang, Xiaoyan Huang, Xiaohuan Pan, et al.

    Rationale: Airway mucus plugs are a prognostic marker in moderate-to-very severe chronic obstructive pulmonary disease (COPD), but their association with respiratory outcomes has been insufficiently evaluated among participants with preserved spirometry and asymptomatic COPD. Objectives: To investigate the association between mucus plugs and respiratory outcomes among participants with COPD and with preserved spirometry. Methods: This prospective community-based cohort study was conducted in China, from July 2019 to September 2024. Eligible participants completed baseline questionnaires, spirometry, and chest CT with follow-up. Mucus plugs were categorized as affecting 0, 1–2, or ≥ 3 lung segments. Respiratory outcomes included exacerbations, lung function decline, and spirometry-defined COPD development. Measurements and Main Results: Overall, 1,939 participants (COPD: 847; preserved spirometry: 1,092) were included, and 1,740 (89%) completed the 3-year follow-up. Among participants with preserved spirometry, those with 1–2 or ≥ 3 mucus plugs had a higher exacerbation risk (RR 1.22, 95%CI 1.01–1.48; RR 1.42, 95%CI 1.11–1.81, respectively) than those without mucus plugs. Participants with ≥3 mucus plugs had a higher risk of spirometry-defined COPD development (18.2% vs. 7.6%, RR 1.71, 95%CI 1.05–2.78) and faster annual decline in FEV1/FVC than those without mucus plugs. Among participants with COPD, with mild-to-moderate COPD, or with asymptomatic COPD, the presence of ≥ 3 mucus plugs were associated with a higher total and moderate-to-severe exacerbation risk. Conclusions: Baseline airway mucus plugs potentially associated with future exacerbations in participants with preserved spirometry and COPD, and may suggest an increased risk of spirometry-defined COPD development in those with preserved spirometry.

  • Efficacy and Safety of Ensifentrine in Chinese Patients with Chronic Obstructive Pulmonary Disease: The ENHANCE-CHINA Randomized Clinical Trial

    by Yumin Zhou, Charlie Chen, Zihui Wang, Fan Wu, Dongbo Tian, Zuke Xiao Xiao, Jie Cao, Feng Xu, Junzhen Gao, Juan Chen, et al.

    Background: Ensifentrine, a novel PDE 3/4 inhibitor, has demonstrated significantly improved lung function and reduced exacerbation in previously trials, predominantly conducted in western populations. However, efficacy and safety data on its use in COPD patients of Chinese remain limited. Therefore, we aimed to evaluate the efficacy and safety of nebulized ensifentrine compared with placebo in Chinese participants with COPD. Methods: A phase III multicenter, randomized, double-blind, placebo-controlled trial was conducted between March 2023 and March 2025. The study enrolled patients with moderate-to-severe symptomatic COPD, randomized to ensifentrine group or placebo group in ratio of 5:3, stratified by maintenance therapy and smoking status. The primary endpoint was the improvement in lung function measured by FEV1 AUC0-12h. Other endpoints include quality of life, symptoms and exacerbation. Results: A total of 525 participants were included in the analysis, with 45.9% receiving concomitant maintenance therapy. Ensifentrine treatment significantly improved average FEV1 AUC0-12h versus placebo (110 ml [95% CI: 69-151], p<0.0001). The improvement in lung function was consistent across clinically relevant subgroups, including participants with and without maintenance therapy, as well as participants with moderate and severe COPD. Ensifentrine treatment significantly improved TDI and showed improvement on ERS and SGRQ versus placebo. Ensifentrine treatment showed the trend of reducing the rate of moderate-to-severe exacerbations and increased time to first exacerbation. Adverse event rates were similar between ensifentrine and placebo groups. Conclusions: Ensifentrine significantly improved lung function, symptoms, and quality of life in a Chinese COPD population.

  • Open Access

    Plasma metabolomic signatures enable the diagnosis and prognosis of chronic obstructive pulmonary disease

    by Chen Li, Jie Yao, Fan Wu, Leqing Zhu, Xiaowen Zhang, Lanzhu Peng, Jieda Cui, Su Fang, Li Lin, Wanli Peng, et al.

    Chronic obstructive pulmonary disease (COPD) is a progressive heterogeneous lung disease driving global illness and death, yet reliable biomarkers for its early diagnosis, molecular subtyping and prognosis are lacking. Here, we conduct targeted plasma metabolomic profiling in two independent, deeply phenotyped cohorts comprising 1344 participants across the full spectrum of COPD severity, with 3-year longitudinal follow-up for 651 subjects. Machine learning integration screens metabolite signatures associated with disease presence, clinical subtypes, and longitudinal outcomes. We identify unique plasma metabolic profiles distinguish COPD patients from healthy people and separate emphysema and small-airway-dominant subtypes with high accuracy in test and validation cohorts. A 27-metabolite panel detects early COPD by capturing metabolic shifts prior to lung function loss. Moreover, specific metabolite subsets independently predicted lung function decline, occurrence of acute exacerbations, and dyspnoea severity. Together, plasma metabolomics yields robust multi-purpose COPD biomarkers, offering an accessible strategy for early screening and personalized clinical risk stratification.

  • Open Access

    Clinical Characteristics and Outcomes of Chronic Obstructive Pulmonary Disease Patients with Expiratory Central Airway Collapse: A Prospective Community-based Cohort Study in China

    by Fangyan Wu, Fan Wu, Kunning Zhou, Bosi Xu, Si Li, Gaoying Tang, Zhishan Deng, Qi Wan, Suyin Huang, Cuiqiong Dai, et al.

    Background: Expiratory central airway collapse (ECAC) may represent an imaging-defined marker of chronic obstructive pulmonary disease (COPD). However, evidence regarding the clinical significance of ECAC in COPD remains limited. Therefore, we aimed to evaluate the presence of ECAC in patients with COPD and its association with respiratory health outcomes. Methods: This study included patients with COPD from a prospective, community-based cohort. The patients underwent spirometry, questionnaires, and paired inspiratory/expiratory chest computed tomography at baseline, and annual exacerbation assessment and spirometry during the 3-year follow-up. ECAC was defined as a reduction in airway cross-sectional area of ≥50% during end-expiration compared with the area during end-inspiration at any of three anatomical levels: the aortic arch, carina, and bronchus intermedius. The outcomes were exacerbation risk and annual rate of lung function decline. Results: 915 patients with COPD were included in the baseline analysis, 892 completed 3-year follow-up. The ECAC detection rate among patients with COPD was 8.7% (80/915). Patients with ECAC had higher total exacerbation (RR=1.50, 95%CI: 1.11–2.04, p=0.009) and moderate-to-severe exacerbation (RR=1.50, 95%CI: 1.07–2.09, p=0.017) risks than those without ECAC. With each additional anatomical level of ECAC, total (RR=1.22, 95%CI: 1.06–1.41, p=0.006) and moderate-to-severe (RR=1.18, 95%CI: 1.01–1.39, p=0.043) exacerbation risks increased. No significant difference was found in lung function decline between patients with and without ECAC. Conclusion: ECAC was associated with a higher exacerbation risk among patients with COPD, suggesting that ECAC may serve as an imaging-based prognostic marker of COPD to guide future exacerbation risk assessment.

  • Open Access

    A novel protective role for SULF1 in chronic obstructive pulmonary disease through systemic compensation and binding to KRT15

    by Yu Liu, Erkang Yi, Yue Xi, Yujie Zuo, Hairong Wang, Xiaoyu Wang, Qianmei Wen, Jingwei Zhang, Xinyue Mei, Haiqing Li, et al.

  • Open Access

    A Pilot Feasibility Study of a Metronome-Cued mHealth System to Promote Walking Exercise in COPD

    by Shuoshuo Wei, Yongfa Hao, Yi Zhang, Faxuan Wang, Ping Zhou, Wangshu Jiang, Yuanyuan Liu, Leiyi Sheng, Yuanyuan Jia, Yumin Zhou, et al.

    Objectives: This study was conducted to develop and evaluate a personalized, home-based metronome-cued walking mHealth system, tailored to individual exercise capacity, and assess its effects on physical activity and quality of life in patients with chronic obstructive pulmonary disease (COPD). Methods: A single-center prospective study was conducted in 40 patients with stable COPD, who were assigned to an intervention group (IG, n = 28) and a control group (CG, n = 12). The IG received a 12-week metronome-cued walking training through the mobile health system. The initial walking intensity was set at 70% of the patient’s baseline level, as determined by the 6 min walking distance (6MWD) and cardiopulmonary exercise testing (CPET). The duration of the training was adjusted according to the Borg scale score and was conducted at least three times per week. The CG received standard care, including lifestyle advice, medications and dietary guidance. Outcomes, including the 6MWD, the COPD Assessment Test (CAT), the Clinical COPD Questionnaire (CCQ), the modified Medical Research Council (mMRC) dyspnea scale, and the Hospital Anxiety and Depression Scale (HADS), were recorded at baseline and week 12. Results: Among 40 enrolled patients, the IG showed improvements compared with the CG. The mean 6MWD increased by 35.32 m (95% CI: 27.84–42.80, p < 0.001) in the IG, with 68% of participants achieving the minimum clinically important difference (MCID) of +35 m. The CAT, the CCQ, the mMRC dyspnea scale, and the HADS also improved in the IG. These findings suggest that the intervention may improve exercise capacity, dyspnea, health-related quality of life and psychological well-being in this patient population. No intervention-related adverse events were observed during the study period. Conclusions: In this small, non-randomized pilot study, a personalized, home-based metronome-cued walking program supported by mHealth technology was feasible and showed preliminary signals of benefit for exercise capacity, dyspnea, quality of life and psychological well-being in patients with COPD.

  • Open Access

    Construction and Validation of Active Case-Finding Tool in Community Participants with Chronic Obstructive Pulmonary Disease Using an Interpretable Machine Learning Approach

    by Heshen Tian, Fan Wu, Chuanqi Sun, Zhishan Deng, Yumin Zhou, Pixin Ran

    Purpose: Early diagnosis is an effective strategy in chronic obstructive pulmonary disease (COPD) prevention. Active case-finding is an effective approach, but traditional tools such as COPD-SQ are limited by outdated data, poor extrapolation, and singular binary prediction. This study aimed to develop an updated, convenient, and interpretable machine learning tool for COPD screening in community participants. Patients and Methods: Data for model training and external validation were obtained from two community-based studies in Guangdong, China. PyCaret and R programming language were used to develop machine learning models. Thirty original items, including demographic data, clinical features, and risk factor data, were initially used. Eleven machine learning classification models were compared, and the least absolute shrinkage and selection operator was further used to shrink predictors. Model performance was evaluated using ROC, AUC, accuracy, sensitivity, specificity, and other metrics. Shapley Additive exPlanations were used to interpret the models. Results: A total of 5381 and 2456 participants from the training and external validation cohorts were included, respectively. In predicting COPD, the AdaBoost model showed the best performance, with an accuracy of 0.846 and an AUC of 0.848. For GOLD classification prediction, the model achieved an overall accuracy of 0.822 and an AUC of 0.816, and identified 83% of moderate-to-severe COPD in the community. In regression analysis, the gradient boosting regression model showed good consistency between predicted and measured FEV1 %pred and FEV1/FVC values. The models also demonstrated good performance in the external validation cohort and were deployed online. Conclusion: We constructed an active case-finding tool with integrated machine learning models for predicting COPD, COPD severity, and lung function parameters using limited clinical data. This tool may help prioritize high-risk individuals for confirmatory spirometry in community settings. Future implementation studies should evaluate its effect on referral efficiency, diagnostic yield, treatment uptake, and long-term outcomes.

  • Open Access

    Attenuated FTO induces necroptosis of alveolar epithelium via the m6A/CYP1B1/ROS/MLKL axis to promote the aggravation of pulmonary emphysema

    by Mindan Wu, Wenjing Wang, Zemin Chen, Yuanlan Yang, Jiawei Yan, Yachao Cui, Peiyu Huang, Feng Zhang, Wei Tu, Wensheng Chen, et al.


  • Open Access

    Compartment-specific phase compensation between pulmonary T-Cell immunity and waning systemic responses in BA.5 breakthrough infection

    by Peiyu Huang, Xinyue Mei, Hao Xu, Qi Wan, Xiaohui Wu, Jieqi Peng, Kunning Zhou, Gang Yang, Li Cheng, Shijun Bu, et al.

    Spatiotemporal coordination of SARS-CoV-2-specific immunity across pulmonary and systemic compartments is poorly defined, especially how chronic lung disea